What Aditum Bio does

Aditum Bio is a privately held biotech venture capital firm founded in 2019 and headquartered at 1111 Broadway Suite 1300 in Oakland, California. The firm operates a distinctive "spin-out incubator" model: it identifies and in-licenses clinic-ready or translational-stage drug candidates from large pharmaceutical and biotech companies (including Novartis, Sosei Heptares, Daewoong Pharmaceutical, Inmagene Biopharmaceuticals, Taisho Pharmaceutical, vTv Therapeutics, Motorpharma, Leads Biolabs, and Mabwell Bioscience), then launches a dedicated portfolio company under the Aditum umbrella to advance each asset through Phase 1 and Phase 2 clinical trials. Each portfolio company runs with its own dedicated leadership team augmented by Aditum's in-house R&D, nonclinical pharmacology, CMC, regulatory affairs, and clinical operations experts, and shares tech-enabled clinical trial execution infrastructure via a partnership with TrialSpark as well as digital patient engagement tools (mobile applications) to support adherence during treatment. Since inception, Aditum has launched 13 portfolio companies spanning obesity, substance use disorders, treatment-resistant depression, renal disease, antivirals, spasticity, autoimmune and inflammatory disorders, and cardiovascular disease.

Aditum's revenue model is hybrid: it deploys institutional LP capital through three sequential venture funds (Fund I launched 2019 at $133M per SEC filings; Fund II launched 2021; Fund III launched 2024 and currently deploying) generating management fees and, on exit, carried interest; it also captures licensing royalties and milestone payments through equity stakes in portfolio companies, with disclosed deal economics ranging from $35M upfront plus $579M milestones (Oblenio/Leads Biolabs) to up to $1B total (Kalexo/Mabwell) and up to $362.50M plus milestones and royalties (Clavis Bio/Fosun Pharma). The go-to-market is relationship-driven and partnership-led: deal flow originates through direct outreach to academic institutions and pharma licensors, while global commercialization is enabled via strategic pharma partners — for example, a five-year collaboration with Shanghai-based Fosun Pharma (announced December 2025) grants Fosun exclusive development, manufacturing, and commercialization rights in China, Hong Kong, and Macau for Clavis Bio programs, with Aditum launching additional subsidiaries for any programs Clavis advances.

The firm has demonstrated its model with a landmark exit — Eli Lilly's August 2023 acquisition of portfolio company Versanis Bio (founded and seeded by Aditum to develop bimagrumab for obesity) for up to $1.925 billion in cash inclusive of milestones — and has continued to scale portfolio company financings, including a $70 million Series B for Tempero Bio (March 2025, led by 8VC) and a $62 million oversubscribed Series B for Oblenio Bio (June 2026, led by Pfizer Ventures). Co-founded by former Novartis CEO Joe Jimenez and former NIBR President Dr. Mark Fishman, Aditum positions itself as serving institutional LPs seeking exposure to de-risked translational-stage biotech opportunities, pharma licensors seeking monetization of deprioritized assets, and patients in underserved disease populations neglected by large pharma and biotech VC funds.

Name

Aditum Bio

Legal name

Aditum Bio Management Company, LLC

Website

https://www.aditumbio.com/

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

11–50 employees

Short description

Aditum Bio is a privately held biotech venture capital firm founded in 2019 that in-licenses translational-stage drug candidates from large pharma, spins out dedicated portfolio companies under its umbrella, and advances them through Phase 1/Phase 2 trials across 13 companies, serving institutional LPs and pharmaceutical licensors.

Ownership category

akta.pro rank

Product category

Biotech Venture Capital

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Corporate Fintech / Insurtech CVC (Financial-services-led CVC) (FSANAHAK)

Keywords

• Biotech venture capital
• Pharmaceutical asset acquisition
• Drug development partnerships
• Translational-stage investment
• Biotech incubator model

Headquarters

HQ city

San Francisco

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Biotech venture capital fund returns (Fund I, Fund II, Fund III): Aditum Bio generates returns by deploying capital from its venture funds (Fund I launched 2019, Fund II launched 2021, Fund III launched 2024) into in-licensed drug candidates, then spinning out individual portfolio companies dedicated to advancing each candidate through Phase 1/Phase 2 trials. Revenue comes from management fees on committed capital and carried interest / equity upside when portfolio companies are sold or go public (e.g., Versanis Bio sold to Eli Lilly for $1.925 billion in August 2023).
2. Licensing royalties and milestones from portfolio companies: Through equity stakes in and licensing arrangements with portfolio companies, Aditum Bio is eligible for milestone payments and royalties tied to clinical and commercial advancement of in-licensed assets. Example: Oblenio Bio's agreement with Leads Biolabs includes up to $35M upfront and near-term payments plus $579M in development, regulatory, and commercialization milestones and royalties on sales; Kalexo Bio deal with Mabwell includes up to USD $1 billion total in upfront/milestone payments plus tiered royalties on global sales.
3. Strategic pharma partnership economics: Aditum Bio negotiates strategic deals with global pharma partners for regional development and commercialization rights to assets advanced through portfolio companies — e.g., the Clavis Bio five-year collaboration with Fosun Pharma provides potential payments to Fosun of up to $362.50 million plus milestones and royalties, with Aditum launching additional subsidiaries for any programs Clavis advances.

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels5 records

Core offering

Aditum Bio is a biotech venture capital firm that identifies, in-licenses, and acquires clinic-ready or translational-stage drug candidates from large pharmaceutical companies, then spins out dedicated portfolio companies under the Aditum umbrella to advance each candidate through Phase 1 and Phase 2 clinical trials. The firm operates through successive venture funds (Fund I launched 2019, Fund II launched 2021, Fund III launched 2024) and has launched 13 portfolio companies targeting underserved disease areas including obesity, depression, substance use disorders, renal disease, infectious diseases, autoimmune and cardiovascular disorders.

Differentiator

Problem solved

Functional benefit

Products and services

• Aditum Bio Fund I
• Aditum Bio Fund II
• Aditum Bio Fund III
• Aditum Bio Biotech Venture Capital Platform

Quantifiable outcome

• 13 portfolio companies launched since 2019
• +11 more outcomes

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

13 partnerships are on record, tiered flagship regional partnership, flagship / core portfolio partnership, major portfolio asset licensor, major exit / strategic acquirer, foundational / repeated asset licensor, core operating partner and founding team member (advisory).

• Fosun Pharma (Shanghai-based)flagship regional partnershipStrategic or Co-development Partner · 19 December 2025Five-year collaboration with newly launched portfolio company Clavis Bio: Fosun holds exclusive rights to develop, manufacture and commercialize partnered assets in China, Hong Kong and Macau, while Clavis Bio can license programs elsewhere. Potential payments to Fosun of up to $362.50 million plus milestones and royalties. Aditum will launch additional subsidiaries for any programs Clavis advances, with Fosun receiving a minority stake in these new companies.
• Mabwell (Shanghai) Bioscience Co., Ltd. (688062.SH)flagship / core portfolio partnershipStrategic or Co-development Partner · 17 September 2025Exclusive global license agreement in conjunction with formation of Kalexo Bio (portfolio company) to develop 2MW7141, a novel dual-target siRNA candidate for lipid management in dyslipidemia and prevention of high-risk atherosclerotic cardiovascular disease (ASCVD) events. Mabwell granted exclusive worldwide rights to develop, manufacture, and commercialize 2MW7141; Mabwell is eligible for up to USD $1 billion total in upfront and milestone payments plus tiered royalties on global sales, including $12 million in non-refundable upfront and near-term cash payments and an equity stake in Kalexo Bio. Aditum Bio will provide funding for Kalexo Bio.
• Leads Biolabs (Nanjing Leads Biolabs Co., Ltd.)flagship / core portfolio partnershipStrategic or Co-development Partner · 7 November 2024Strategic asset licensing and co-development partnership: Leads Biolabs granted Oblenio Bio (an Aditum Bio portfolio company, the thirteenth launched) an exclusive option to develop, manufacture, and commercialize LBL-051, a first-in-class CD19×BCMA×CD3 tri-specific T-cell engager antibody for autoimmune diseases, worldwide. Leads Biolabs is eligible for up to $35M in upfront and near-term payments plus $579M in development, regulatory, and commercialization milestone payments, royalties on sales, and an equity stake in Oblenio Bio. The compound was discovered using Leads Biolabs' proprietary LeadsBody™ platform. In June 2026 Oblenio closed a $62M oversubscribed Series B led by Pfizer Ventures with Aditum participation to advance LBL-051 into clinical development.
• Inmagene Biopharmaceuticalsmajor portfolio asset licensorStrategic or Co-development Partner · 21 September 2023Asset in-licensing partnership in conjunction with formation of Celexor Bio (tenth Aditum Bio company): Inmagene licensed IMG-018, a depleting antibody targeting immunoglobulin-like transcript 7 (ILT7) on plasmacytoid dendritic cells (pDCs), renamed CLXR-901, for autoimmune and inflammatory disorders.
• Eli Lilly and Company (NYSE: LLY)major exit / strategic acquirerStrategic or Co-development Partner · 14 August 2023Strategic acquirer of Versanis Bio (portfolio company founded/seeded by Aditum Bio) for up to $1.925 billion in cash, inclusive of upfront payment and subsequent milestone payments, expanding Lilly's cardiometabolic portfolio to include bimagrumab.
• Daewoong Pharmaceutical Co., Ltd.major portfolio asset licensorStrategic or Co-development Partner · 27 April 2023Asset in-licensing partnership in conjunction with formation of Vitalli Bio (ninth Aditum Bio company): Daewoong licensed a highly selective dual inhibitor of Interleukin-2-Inducible T-Cell Kinase (ITK) and Bruton's Tyrosine Kinase (BTK), renamed VIT-801, anticipated to enter Phase 1 studies in 2023. Vitalli Bio also granted an option to license earlier stage dual-target inhibitors in development by Daewoong.
• Motorpharma, Ltd. (Hungary)major portfolio asset licensorStrategic or Co-development Partner · 15 November 2021Asset in-licensing partnership in conjunction with formation of Motric Bio (seventh Aditum Bio company): Motorpharma licensed a myosin-2 inhibitor that has shown selective inhibition of fast skeletal muscle, to develop a therapy for spasticity associated with neurological injuries and disease (stroke, multiple sclerosis, etc.). Motorpharma is a spin-off of Eötvös Loránd University, Hungary.
• Novartis (multiple asset in-licensing transactions)foundational / repeated asset licensorStrategic or Co-development Partner · 7 September 2021Recurring asset licensing counterparty: Via Nova Therapeutics was founded in August 2021 following the in-licensing of four preclinical antiviral programs (influenza A, human rhinovirus, BK polyomavirus, adenovirus) from Novartis. Aditum Bio also licensed bimagrumab from Novartis (the foundation for Versanis Bio, sold to Eli Lilly for up to $1.925B in August 2023). Additional portfolio asset licensors include Celexor Bio/Inmagene (co-developing IMG-020 izokibep).
• Taisho Pharmaceutical Co., Ltd.major portfolio asset licensorStrategic or Co-development Partner · 30 June 2021Asset licensing partnership: Taisho Pharmaceutical in-licensed ANC-501, a selective vasopressin 1b receptor (V1b) antagonist, to Aditum Bio's portfolio company Ancora Bio (later renamed EmbarkNeuro) for the treatment of treatment-resistant depression. The asset is a Phase II-ready, first-in-class V1b receptor antagonist that entered Phase 2 trials in November 2022.
• TrialSparkcore operating partnerTechnology or Integration · 30 June 2021Technology-driven clinical trial execution partner: TrialSpark operates as an alternative to traditional CROs, with a digital platform that optimizes all aspects of a clinical trial, enabling faster trial completion, higher data quality, and a more patient-centric experience. Aditum Bio uses TrialSpark to complete clinical trials faster and at lower cost than traditional trials; TrialSpark partners with doctors in community settings to create trial and referral sites within their existing practices, accelerating recruitment rates.
• vTv Therapeutics (NASDAQ:VTVT)major portfolio asset licensorStrategic or Co-development Partner · 15 December 2020Asset in-licensing partnership in conjunction with formation of Anteris Bio (third Aditum Bio company): vTv Therapeutics licensed ANT-401, a small molecule activator of Nrf2 (via Bach1 inhibition), for the treatment of renal disease.
• Sosei Heptares (4565:JP)major portfolio asset licensorStrategic or Co-development Partner · 2 November 2020Asset licensing partnership: TMP-301 (mGluR5 negative allosteric modulator for substance use disorders and anxiety) was in-licensed from Sosei Heptares to form Tempero Bio, Aditum's second portfolio company. Sosei Heptares is Japan-listed; its StaR®/SBDD platform underpins the asset. Tempero Bio subsequently received FDA IND clearance (Jan 2023) and a $5.3M NIDA grant, and closed a $70M Series B in March 2025.
• Paul Sekhri (co-founder, eGenesis Inc.)founding team member (advisory)Strategic or Co-development Partner · 1 January 2019Co-founder of Aditum Bio alongside Joe Jimenez and Mark Fishman; President and CEO of eGenesis Inc., who remained at eGenesis but contributed to the formation of the firm in 2019.

Scale indicators15 records

Recent moves17 records

Expansion highlights5 records

Direct peers

• BridgeBio Pharma: BridgeBio is an asset-centric biotech that licenses and develops genetically validated therapies across multiple therapeutic areas, similarly spinning out focused subsidiaries. The 'asset-first, company-second' operating philosophy closely mirrors Aditum's incubator approach.
• Atlas Venture: Atlas Venture is a leading early-stage biotech VC firm that co-led the $70M Series A for Aditum's Versanis Bio. It is a direct strategic peer with a comparable company-creation approach focused on building therapeutic-area-focused biotechs from inception.
• Forbion: Forbion is a leading European biotech VC with a strong company-creation and late-stage growth practice. It is comparable to Aditum in deploying capital into translational-stage biotechs and building dedicated companies around de-risked assets.
• Medicxi: Medicxi is a European asset-centric biotech VC firm that co-led the $70M Series A for Aditum's Versanis Bio. It is one of the most direct strategic peers in the asset-centric biotech VC space, with comparable fund sizes and a similar translational-stage focus.
• Roivant Sciences: Roivant operates a near-identical 'Vant' model of in-licensing deprioritized pharma assets and spinning out dedicated subsidiaries to advance them. Both firms use translational-stage sourcing, dedicated portfolio companies, and shared in-house operating infrastructure, making Roivant the closest public-market comparable to Aditum's spin-out model.
• Cydan Development: Cydan is an asset-creation biotech incubator that identifies promising therapeutic assets and spins out dedicated companies to develop them, mirroring Aditum's model with a sharper focus on rare diseases. Operates a near-identical in-license-and-spin-out framework.

Broad incumbents

• Khosla Ventures: Khosla Ventures is a large generalist VC firm with a significant biotech practice that co-invested in Aditum's Tempero Bio ($70M Series B in March 2025). It is a broader incumbent in the biotech VC space with adjacent translational-stage exposure.
• ARCH Venture Partners: ARCH is a large, established biotech VC firm with a long track record in company formation. It represents a broader incumbent peer in the translational-stage biotech VC space, though with a wider therapeutic-area mandate and significantly larger AUM.
• OrbiMed Advisors: OrbiMed is one of the largest healthcare-dedicated investment firms globally, with broad public and private biotech exposure. It is a broader incumbent in the biotech VC space, offering partial overlap with Aditum's translational-stage deployment model but at materially greater AUM scale.

Emerging players

• Curie.Bio: Curie.Bio is a newer biotech VC firm offering 'founder-friendly' asset incubation, with overlap in translational-stage deal sourcing and shared operating infrastructure. It represents a more recent entrant with a similar company-creation model.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles15 records

Subsidiaries12 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments5 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Aditum Bio